Stock Price Quote

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE1373.95-0.95 (-0.07 %)
PREV CLOSE ( ) 1374.90
OPEN PRICE ( ) 1376.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 80275
TODAY'S LOW / HIGH ( )1355.50 1409.00
52 WK LOW / HIGH ( )1237.9 1909.55
NSE1370.90-3 (-0.22 %)
PREV CLOSE( ) 1373.90
OPEN PRICE ( ) 1369.60
BID PRICE (QTY) 1370.90 (4)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 181983
TODAY'S LOW / HIGH( ) 1355.00 1410.00
52 WK LOW / HIGH ( )1200 1910
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 25-01 2007
Management Info
Amit Indubhushan Bakshi - Chairman Amit Indubhushan Bakshi - Managing Director
Registered Office

Address Shivarth Ambit, Plot No. 142/2,Ramdas Road, Off S B R,Near Swati Bungalows, Bodakdev,
Ahmedabad,
Gujarat-380054

Phone 079 30451000 / 1001

Email eris@erislifesciences.com

Website www.eris.co.in

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

11May Eris Lifesciences informs about allotm
Eris Lifesciences has informed that an allotment of 24,396 equity shares..
24Apr Eris Lifesciences informs about newspa
Pursuant to Regulation 47 of the Securities and Exchange Board of India..
21Mar Eris Lifesciences to launch generic Se
Eris Lifesciences is all set to launch generic Semaglutide under the bra..
05Mar Eris Lifesciences informs about instit
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclos..
24Feb Eris Lifesciences inks pact with Natco
Eris Lifesciences has entered into strategic partnership with Natco Phar..
MORE

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit30.8999999999998773.899999999998
Gross Profit 38.8999999999998 1200.5
Operating Profit 1024.25220.6
Net Sales 3152.916977.5
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  27934.60 (1.52%)
M.Cap ( in Cr)59359.08
Pfizer (BSE)
peergroup  4939.05 (5.36%)
M.Cap ( in Cr)22595.03
Astrazeneca Pharma I (BSE)
peergroup  8488.45 (1.66%)
M.Cap ( in Cr)21221.13
Hester Biosciences (BSE)
peergroup  1834.05 (5.67%)
M.Cap ( in Cr)1560.20
Senores Pharmaceutic (BSE)
peergroup  1052.35 (10.22%)
M.Cap ( in Cr)4846.45
MORE

Shareholding Pattern

PROMOTERS 53.92%
NON-INSTITUTION 19.33%
MUTUAL FUNDS/UTI 18.22%
FI/BANKS/INSURANCE 1.31%
GOVERNMENT 0%
FII 0%
MORE

About Eris Lifesciences Ltd.

Eris Lifesciences Ltd. was incorporated in the year 2007. Its today's share price is 1373.95. Its current market capitalisation stands at Rs 19038.45 Cr. In the latest quarter, company has reported Gross Sales of Rs. 17367.1 Cr and Total Income of Rs.17332.6 Cr. The company's management includes Prashant Gupta, Kalpana Unadkat, Sujesh Vasudevan, Kaushal Shah, Inderjeet Singh Negi, Amit Indubhushan Bakshi, Amit Indubhushan Bakshi, Krishnakumar Vaidyanathan, Milind Talegaonkar.

It is listed on the BSE with a BSE Code of 540596 , NSE with an NSE Symbol of ERIS and ISIN of INE406M01024. It's Registered office is at Shivarth Ambit, Plot No. 142/2,Ramdas Road, Off S B R,Near Swati Bungalows, BodakdevAhmedabad-380054, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, RR Shah & Associate

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter SCORES complaints – April 2026 Online Grievance Portal – SCORES Online Dispute Resolution Portal – ODR Fee Calculator UPI ID - QR Code & Forms Contact Us
Mutual Funds About Nirmal Bang Wealth Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
NPS NPS Forms and Guidelines NPS-AML Policy
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data Important Update
Other Links Disclaimer Privacy Policy Policies and Procedures Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SEBI Scores RMS Policy Inspection SORM Policy - NBEPL CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023 FY-2023-2024 FY-2024-2025
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker RA NBEPL Investor Charter RA NBSPL Investor Charter Investor Complaints -RA Investor Complaints-NBEPL Investor NBCPL Investor NBEPL RA Investor NBSPL-RA
Evoting
NSDL Evoting CDSL Evoting
Compliance Annual report
NBSPL ACR Report Signed Annexure – NBSPL NBEPL ACR Report Signed Annexure – NBEPL
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’s Surrendered List of AP’s KYC Activation Process Voluntary Freezing Blocking of Online Trading Account Internal Shortage Policy MCXCCL Client Reports Policy For GTC/GTD RBI Guidelines Transfer of Funds via SEBI-Validated UPI ID MTF Terms
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatment NBSPL Policy of AML NBEPL Policy of AMLNBSPL Policy of SurveillanceNBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For Any Legal Department Grievances – Level 1, Please Get In Touch With Mr. Bhavin Pandya On 022-6273 9232 Or Write A Mail To bhavin.pandya@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Legal Department Grievances – Level 2, Please Get In Touch With Mr. Kishor Kumar Agrawal On 022-6273 9252/9253 Or Write A Mail To kishorkumar.agrawal@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Compliance Grievances / other grievances , Please Get In Touch With Mr. Samir Kamdar On 022-62739395/9396 Or Write A Mail To samir.kamdar@nirmalbang.com With Subject line As Grievances/Complaint.     |    
IMPORTANT LINKS: SEBI BSE NSE MCX CDSL NSDL NCDEX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.